EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

A pilot randomized, placebo-controlled, double-blind study of omega-3 fatty acids to prevent paclitaxel-associated acute pain syndrome in breast cancer patients: Alliance A22_Pilot2

Bernard Tawfik iD, Zoneddy R Dayao, Ursa Abigail Brown-Glaberman, V Shane Pankratz, Jacqueline M Lafky, Charles L Loprinzi, Debra L Barton

Supportive Care in Cancer · 2023

DOI: 10.1007/s00520-023-08082-x ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Supportive Care in Cancer, 2023. Verfasst von Bernard Tawfik und 6 weiteren Autor:innen. Beteiligte Einrichtung: UNM Comprehensive Cancer Center, Division of Hematology/Oncology, MSC 07-4025, 1 University of New Mexico, Albuquerque, NM, 87131-0001, USA. BTawfik@…. Hauptthemen laut MEDLINE: Breast Neoplasms, Acute Pain, Fatty Acids, Omega-3, Peripheral Nervous System Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Paclitaxel is associated with an acute pain syndrome (P-APS- and chronic chemotherapy-induced peripheral neuropathy (CIPN). P-APS is associated with higher risk of CIPN. Omega-3 fatty acids have well-established anti-inflammatory and neuroprotective properties. The primary purpose of this pilot study was to assess whether omega-3 fatty acids could decrease P-APS and thus CIPN. METHODS: Patients scheduled to receive weekly paclitaxel for breast cancer were randomized to receive 4 g of omega-3 acid ethyl esters (Lovaza) or placebo, beginning 1 week prior and continued until paclitaxel was stopped. Patients completed acute pain questionnaires at baseline, daily after each treatment, and 1 month after completion of therapy. RESULTS: Sixty patients (49 evaluable) were randomized to treatment versus placebo. Seventeen (68.0%) patients receiving the omega-3 fatty acids intervention experienced P-APS, compared to 15 (62.5%) of those receiving placebo during the first week of treatment (p = 0.77). Over the full 12-week study, 21 (84.0%) patients receiving the omega-3 fatty acid intervention experienced P-APS, compared to 21 (87.5%) of those receiving placebo (p = 1.0). Secondary outcomes suggested that those in the intervention arm used more over-the-counter analgesics (OR: 1.65, 95% CI: 0.72-3.78, p = 0.23), used more opiates (OR: 2.06, 95% CI: 0.55-7.75, p = 0.28), and experienced higher levels of CIPN (12.8, 95% CI: 7.6-19.4 vs. 8.4, 95% CI: 4.6-13.2, p = 0.21). CONCLUSIONS: The results of this pilot study do not support further study of the use of omega-3 fatty acids for the prevention of the P-APS and CIPN. TRIAL REGISTRATION: Number: NCT01821833.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAcute PainFatty Acids, Omega-3Peripheral Nervous System DiseasesHumansFemalePaclitaxelPilot ProjectsDouble-Blind Method

Stichwörter der Autor:innen

Breast cancerChronic chemotherapy-induced peripheral neuropathy (CIPN)Omega-3 fatty acidsPaclitaxelPaclitaxel acute pain syndrome

Substanzen

PaclitaxelFatty Acids, Omega-3

Autor:innen und Institutionen

  • UNM Comprehensive Cancer Center, Division of Hematology/Oncology, MSC 07-4025, 1 University of New Mexico, Albuquerque, NM, 87131-0001, USA. BTawfik@salud.unm.edu.
  • School of Medicine, University of New Mexico, Albuquerque, NM, USA. BTawfik@salud.unm.edu.
  • UNM Comprehensive Cancer Center, Division of Hematology/Oncology, MSC 07-4025, 1 University of New Mexico, Albuquerque, NM, 87131-0001, USA.
  • School of Medicine, University of New Mexico, Albuquerque, NM, USA.
  • Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, USA.
  • Mayo Clinic, Rochester, MN, USA.

ORCID-Profile: Bernard Tawfik

Förderung

  • NCI NIH HHS

Zitieren

APA

Tawfik, B., Dayao, Z. R., Brown-Glaberman, U. A., Pankratz, V. S., Lafky, J. M., Loprinzi, C. L., & Barton, D. L. (2023). A pilot randomized, placebo-controlled, double-blind study of omega-3 fatty acids to prevent paclitaxel-associated acute pain syndrome in breast cancer patients: Alliance A22_Pilot2. Supportive Care in Cancer. https://doi.org/10.1007/s00520-023-08082-x

Vancouver

Tawfik B, Dayao ZR, Brown-Glaberman UA, Pankratz VS, Lafky JM, Loprinzi CL, et al. A pilot randomized, placebo-controlled, double-blind study of omega-3 fatty acids to prevent paclitaxel-associated acute pain syndrome in breast cancer patients: Alliance A22_Pilot2. Supportive Care in Cancer. 2023. doi:10.1007/s00520-023-08082-x

BibTeX
@article{Tawfik2023,
  author = {Tawfik, Bernard and Dayao, Zoneddy R and Brown-Glaberman, Ursa Abigail and Pankratz, V Shane and Lafky, Jacqueline M and Loprinzi, Charles L and Barton, Debra L},
  title = {A pilot randomized, placebo-controlled, double-blind study of omega-3 fatty acids to prevent paclitaxel-associated acute pain syndrome in breast cancer patients: Alliance A22_Pilot2},
  journal = {Supportive Care in Cancer},
  year = {2023},
  doi = {10.1007/s00520-023-08082-x}
}
Kostenlos starten →